The current landscape of antifibrotic therapy across different organs

We have systematically reviewed all current and recently finished clinical trials involved in the development of new antifibrotic drugs.

The currrent landscape of antifibrotic therapy across different organs

Request PDF | The currrent landscape of antifibrotic therapy across different organs: A systematic approach | Fibrosis is a common ...

The current landscape of antifibrotic therapy across different organs ...

Although there have been previous reviews on anti-fibrotic drug development in individual fibrotic diseases such as lung [159], liver [160,161], kidney [162], ...

The current landscape of antifibrotic therapy across different organs

We have systematically reviewed all current and recently finished clinical trials involved in the development of new antifibrotic drugs, and the ...

A Review of the Current Landscape of Anti-Fibrotic Medicines

We reviewed the current efforts in developing novel anti-fibrotic medicines focusing on lung, heart, kidney, liver and skin fibrosis.

THE CURRRENT LANDSCAPE OF ANTIFIBROTIC THERAPY ...

Fibrosis is a common pathological process that can affect virtually all the organs, but there are hardly any effective therapeutic options.

The current landscape of antifibrotic therapy across different organs

The current landscape of antifibrotic therapy across different organs: A systematic approach ... Pohlers, TGF-β and fibrosis in different organs—molecular pathway ...

The currrent landscape of antifibrotic therapy across different organs ...

Fibrosis is a common pathological process that can affect virtually all the organs, but there are hardly any effective therapeutic options.

Current and Future Treatment Landscape for Idiopathic Pulmonary ...

This review discusses the key pathogenetic concepts for the development of new antifibrotic agents, presents the newest data on approved ...

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human ...

Nonalcoholic fatty liver disease (NAFLD) is characterized by fat accumulation within the liver (hepatic steatosis) without secondary causes, ...

Antifibrotic therapy in progressive pulmonary fibrosis: a review of ...

Real-world experience from the UK suggests concomitant immunomodulatory and antifibrotic therapy is commonly prescribed in patients with PPF [Citation78].

Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis

On the other hand, most targeted therapies exert antifibroblast, anti-inflammatory, and antiproliferative effects (Fig. 3C, bottom). Pirfenidone ...

Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the ...

We found that stromal reengineering to normalize tumor microenvironments with antifibrotic therapy markedly disrupts transport barriers associated with PDA (Fig ...

Recent Advancements in Antifibrotic Therapies for Regression of ...

These therapies include the use of growth factors, cytokines, miRNAs, monoclonal antibodies, stem-cell-based approaches, and other approaches that target the ...

Novel Anti-fibrotic Therapies - Frontiers

Fibrosis is a critical stage of many chronic diseases that can lead to organ dysfunction, illness and death. The burden associated with fibrosis is staggering ...

Treatment Landscape Surrounding Anti-Fibrotic Agents

It's similar for these other fibrotic lung diseases that are included under the column of progressive pulmonary fibrosis. Nintedanib doesn't ...

Pharmacotherapy for idiopathic pulmonary fibrosis

In this regard, it is hoped that the ongoing clinical trial using combined nintedanib and sildenafil will yield positive results. Other novel treatment ...

Development of antifibrotic therapy for stricturing Crohn's disease

Already developed antifibrotic therapies in organs such as the lung, liver, kidney, bone, heart, and skin can shed light on intestinal fibrosis and ultimately ...

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

In terms of the development of anti-fibrotic therapeutics, the approval of two agents, pirfenidone (Esbriet) and nintedanib (Ofev), which slow disease ...

Treatment of idiopathic pulmonary fibrosis and progressive ...

Significant disease progression in an individual otherwise tolerating their current anti-fibrotic agent should not necessarily prompt conversion ...